Interaction Checker

Interaksi Hidroksiklorokuin

Hidroksiklorokuin (Plaquenil), golongan obat yang memperpanjang interval QT, memiliki 209 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 122 mayor, 58 moderat, 29 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (122)

  • AkarbosaantidiabetesMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Alfuzosinpenyekat alfaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Alogliptin dan metforminpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • AmiodaronantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Amitriptilinantidepresan trisiklikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Arsen trioksidaobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • AsenapinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Beksagliflozinpenghambat SGLT2Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Dapagliflozinpenghambat SGLT2Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Dapagliflozin dan metforminpenghambat SGLT2Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Dekstrometorfan dan kuinidinobat serotonergikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Deutetrabenazinpenghambat VMAT2Mayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • DisopiramidantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • DofetilidantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • DronedaronantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Droperidolantagonis dopaminMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Dulaglutidagonis reseptor GLP-1Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Empagliflozin dan metforminpenghambat SGLT2Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Emtrisitabin, rilpivirin, dan tenofovirantiretroviralMayor

    Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (label Emtrisitabin, rilpivirin, dan tenofovir, Peringatan dan perhatian)

  • Eritromisinantibiotik makrolidaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • EsitalopramSSRIMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • FenobarbitalbarbituratMayor

    Drugs that Prolong the QT Interval : Avoid concomitant use. (label Fenobarbital, Interaksi obat)

  • FingolimodimunosupresanMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • FlekainidantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Flukonazolantijamur azolMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • FluoksetinSSRIMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • FosfomisinantibiotikMayor

    Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (label Fosfomisin, Interaksi obat)

  • FoskarnetantivirusMayor

    (See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (label Foskarnet, Interaksi obat)

  • GlibenklamidsulfonilureaMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • GlimepiridsulfonilureaMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • GlipizidsulfonilureaMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Glipizid dan metforminsulfonilureaMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Granisetronobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • HaloperidolantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • HidroksizinantihistaminMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • IbutilidantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • IloperidonantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Insulin aspartinsulinMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Insulin degludekinsulinMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Insulin detemirinsulinMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Insulin glargininsulinMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Insulin lisproinsulinMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Insulin reguler (manusia)insulinMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • IvabradinMayor

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (label Ivabradin, Peringatan dan perhatian)

  • Kanagliflozinpenghambat SGLT2Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Ketokonazolantijamur azolMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Klaritromisinantibiotik makrolidaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • KlorokuinantimalariaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • KlorpromazinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • KlozapinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • KuetiapinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • KuinidinantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • KuininantimalariaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • LevofloksasinfluorokuinolonMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Linagliptin dan metforminpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Loperamidobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Lopinavir dan ritonavirantiretroviralMayor

    Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (label Lopinavir dan ritonavir, Peringatan dan perhatian)

  • MetadonopioidMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • MetforminbiguanidMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • MiglitolantidiabetesMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • MirtazapinantidepresanMayor

    Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (label Mirtazapin, Interaksi obat)

  • MoksifloksasinfluorokuinolonMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • NateglinidmeglitinidMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Nilotinibobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • OfloksasinfluorokuinolonMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • OksaliplatinMayor

    Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (label Oksaliplatin, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Ondansetronobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PaliperidonantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PazopanibMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • PenisilaminMayor

    Penicillamine should not be used in patients who are receiving concurrently gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone because these drugs are also associated with similar serious hematologic and renal adverse reactions. (label Penisilamin, Perhatian)

  • Pentamidinobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PimavanserinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PimozidantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PioglitazontiazolidindionMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Pioglitazon dan glimepiridtiazolidindionMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Pioglitazon dan metformintiazolidindionMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Pitolisantobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Posakonazolantijamur azolMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • ProkainamidantiaritmiaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PrometazinantihistaminMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Prometazin dan dekstrometorfanantihistaminMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Prometazin dan kodeinopioidMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • PropafenonantiaritmiaMayor

    • Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (label Propafenon, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • RepaglinidmeglitinidMayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • RisperidonantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Semaglutidagonis reseptor GLP-1Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • SertralinSSRIMayor

    Avoid the concomitant use of drugs known to prolong the QTc interval. (label Sertralin, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Avoid concomitant use of cimetidine 7.9 Rifampicin Lack of efficacy of hydroxychloroquine was reported when rifampicin was concomitantly administered. (label Hidroksiklorokuin, Interaksi obat)

  • SiprofloksasinfluorokuinolonMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Sitagliptinpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • SitalopramSSRIMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • SolifenasinantikolinergikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Sotalolpenyekat betaMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • TakrolimusimunosupresanMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Tamoksifenmodulator reseptor estrogen selektifMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Tetrabenazinpenghambat VMAT2Mayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • TioridazinantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Tirzepatidagonis reseptor GLP-1Mayor

    Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • TolterodinantikolinergikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Toremifenmodulator reseptor estrogen selektifMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • TramadolopioidMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Tramadol dan parasetamolopioidMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • TrazodonantidepresanMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Valbenazinpenghambat VMAT2Mayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Mayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • VenlafaksinSNRIMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • VepdegestrantMayor

    Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (label Vepdegestrant, Peringatan dan perhatian)

  • Vorikonazolantijamur azolMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • ZiprasidonantipsikotikMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

Interaksi moderat (58)

  • AlkoholAlkoholModerat

    Some of the cases were associated with other risk factors for hepatic injury (e.g., alcohol use, concomitant hepatotoxic medications). (label Hidroksiklorokuin, Peringatan dan perhatian)

  • Ampisilinantibiotik penisilinModerat

    Ampicillin In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. (label Hidroksiklorokuin, Interaksi obat)

  • Ampisilin dan sulbaktamantibiotik penisilinModerat

    Ampicillin In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. (label Hidroksiklorokuin, Interaksi obat)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (label Hidroksiklorokuin, Interaksi obat)

  • Arformoterolagonis beta-adrenergikModerat

    MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (label Arformoterol, Interaksi obat)

  • Artikain dan epinefrinanestetik lokalModerat

    …ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase… (label Artikain dan epinefrin, Interaksi obat)

  • AtovakuonantimalariaModerat

    Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (label Hidroksiklorokuin, Interaksi obat)

  • Atovakuon dan proguanilantimalariaModerat

    Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (label Hidroksiklorokuin, Interaksi obat)

  • Bismut subsitrat, metronidazol, dan tetrasiklinantibiotikModerat

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (label Bismut subsitrat, metronidazol, dan tetrasiklin, Peringatan dan perhatian)

  • Bupivakainanestetik lokalModerat

    • Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (label Bupivakain, Interaksi obat)

  • Bupivakain dan epinefrinanestetik lokalModerat

    • Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (label Bupivakain dan epinefrin, Interaksi obat)

  • BuprenorfinopioidModerat

    The risk of combining buprenorphine with other QT-prolonging agents is not known. (label Buprenorfin, Peringatan dan perhatian)

  • Buprenorfin dan naloksonopioidModerat

    The risk of combining buprenorphine with other QT-prolonging agents is not known. (label Buprenorfin dan nalokson, Peringatan dan perhatian)

  • DarunavirantiretroviralModerat

    Antimalarial : artemether/lumefantrine ↓ artemether ↓ dihydroartemisinin ↑ lumefantrine ↔ darunavir The combination of PREZISTA/ritonavir and artemether/lumefantrine can be used without dose adjustments. (label Darunavir, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    Antimalarial: artemether/lumefantrine artemether: effect unknown lumefantrine: effect unknown Monitor for a potential decrease of antimalarial efficacy or potential QT prolongation. (label Darunavir dan kobisistat, Interaksi obat)

  • Desflurananestetik umumModerat

    Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Desfluran, Peringatan dan perhatian)

  • Digoksinglikosida digitalisModerat

    Digoxin Concomitant PLAQUENIL and digoxin therapy may result in increased serum digoxin levels. (label Hidroksiklorokuin, Interaksi obat)

  • EfavirenzantiretroviralModerat

    QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (label Efavirenz, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (label Efavirenz, lamivudin, dan tenofovir, Interaksi obat)

  • EribulinModerat

    QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (label Eribulin, Peringatan dan perhatian)

  • EtravirinantiretroviralModerat

    Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (label Etravirin, Interaksi obat)

  • FentanilopioidModerat

    …prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (label Fentanil, Peringatan dan perhatian)

  • Formoterolagonis beta-adrenergikModerat

    …Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (label Formoterol, Interaksi obat)

  • GoserelinModerat

    Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Goserelin, Peringatan dan perhatian)

  • HeparinantikoagulanModerat

    Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (label Heparin, Interaksi obat)

  • HidrokodonopioidModerat

    This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (label Hidrokodon, Peringatan dan perhatian)

  • Isoflurananestetik umumModerat

    Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Isofluran, Peringatan dan perhatian)

  • Kloroprokainanestetik lokalModerat

    …procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (label Kloroprokain, Perhatian)

  • Lapatinibpenghambat P-glikoproteinModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • LeuprorelinModerat

    Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Leuprorelin, Peringatan dan perhatian)

  • Lidokain dan epinefrinanestetik lokalModerat

    Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (label Lidokain dan epinefrin, Interaksi obat)

  • Lidokain dan prilokainanestetik lokalModerat

    …prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (label Lidokain dan prilokain, Interaksi obat)

  • Lofeksidinagonis alfa-adrenergikModerat

    Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (label Lofeksidin, Peringatan dan perhatian)

  • MeflokuinantimalariaModerat

    Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (label Hidroksiklorokuin, Interaksi obat)

  • Mepivakainanestetik lokalModerat

    …procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (label Mepivakain, Interaksi obat)

  • MetotreksatimunosupresanModerat

    Methotrexate Concomitant use of PLAQUENIL and methotrexate may increase the incidence of adverse reactions. (label Hidroksiklorokuin, Interaksi obat)

  • MetronidazolantibiotikModerat

    Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (label Metronidazol, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Moderat

    There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (label Mifepriston, Peringatan dan perhatian)

  • Natrium bikarbonatantasidaModerat

    Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (label Hidroksiklorokuin, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (label Hidroksiklorokuin, Interaksi obat)

  • PasireotidModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PirimetaminantimalariaModerat

    Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (label Hidroksiklorokuin, Interaksi obat)

  • PonesimodimunosupresanModerat

    Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (label Ponesimod, Interaksi obat)

  • PrazikuantelModerat

    Praziquantel Chloroquine has been reported to reduce the bioavailability of praziquantel. (label Hidroksiklorokuin, Interaksi obat)

  • Prilokain dan epinefrinanestetik lokalModerat

    …ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration… (label Prilokain dan epinefrin, Interaksi obat)

  • PrimakuinantimalariaModerat

    Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (label Hidroksiklorokuin, Interaksi obat)

  • RifapentinantibiotikModerat

    …quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol… (label Rifapentin, Interaksi obat)

  • RilpivirinantiretroviralModerat

    In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (label Rilpivirin, Peringatan dan perhatian)

  • Rokuroniumpenyekat neuromuskularModerat

    QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (label Rokuronium, Peringatan dan perhatian)

  • Ropivakainanestetik lokalModerat

    …ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be… (label Ropivakain, Interaksi obat)

  • Sevoflurananestetik umumModerat

    Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Sevofluran, Peringatan)

  • SiklosporinimunosupresanModerat

    Cyclosporine An increased plasma cyclosporin level was reported when cyclosporin and PLAQUENIL were co-administered. (label Hidroksiklorokuin, Interaksi obat)

  • Sinakalsetpenghambat CYP2D6Moderat

    QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (label Sinakalset, Peringatan dan perhatian)

  • SorafenibModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • SunitinibModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • TafenokuinantimalariaModerat

    Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (label Hidroksiklorokuin, Interaksi obat)

  • TriptorelinModerat

    Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Triptorelin, Peringatan dan perhatian)

  • Umeklidinium dan vilanterolantikolinergikModerat

    …like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (label Umeklidinium dan vilanterol, Interaksi obat)

Penyebutan minor (29)

  • Asam valproatantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • BrivarasetamantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • Divalproeks (valproat)antikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • EslikarbazepinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • EtosuksimidantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • FelbamatantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • FenitoinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • FosfenitoinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • GabapentinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • Kanabidiol (obat resep)antikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • KarbamazepinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • KlobazambenzodiazepinMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • KlonazepambenzodiazepinMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • LakosamidantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • LamotriginantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • LevetirasetamantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • MetsuksimidantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • OkskarbazepinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • PerampanelantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • Pilokarpinagonis kolinergikMinor

    …performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (label Pilokarpin, Interaksi obat)

  • PregabalinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • PrimidonantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • RufinamidantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • SenobamatantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • TiagabinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • TopiramatantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • VigabatrinantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

  • ZonisamidantikonvulsanMinor

    Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (label Hidroksiklorokuin, Interaksi obat)

Periksa Hidroksiklorokuin terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.